Deletion of the EP402R Gene from the Genome of African Swine Fever Vaccine Strain ASFV-G-∆I177L Provides the Potential Capability of Differentiating between Infected and Vaccinated Animals

Manuel V. Borca,Elizabeth Ramirez-Medina,Nallely Espinoza,Ayushi Rai,Edward Spinard,Lauro Velazquez-Salinas,Alyssa Valladares,Ediane Silva,Leeanna Burton,Amanda Meyers,Jason Clark,Ping Wu,Cyril G. Gay,Douglas P. Gladue

DOI: https://doi.org/10.3390/v16030376

2024-02-29

Viruses

Abstract:The African swine fever virus (ASFV) mutant ASFV-G-∆I177L is a safe and efficacious vaccine which induces protection against the challenge of its parental virus, the Georgia 2010 isolate. Although a genetic DIVA (differentiation between infected and vaccinated animals) assay has been developed for this vaccine, still there is not a serological DIVA test for differentiating between animals vaccinated with ASFV-G-∆I177L and those infected with wild-type viruses. In this report, we describe the development of the ASFV-G-∆I177L mutant having deleted the EP402R gene, which encodes for the viral protein responsible for mediating the hemadsorption of swine erythrocytes. The resulting virus, ASFV-G-∆I177L/∆EP402R, does not have a decreased ability to replicates in swine macrophages when compared with the parental ASFV-G-∆I177L. Domestic pigs intramuscularly (IM) inoculated with either 102 or 106 HAD50 of ASFV-G-∆I177L/∆EP402R remained clinically normal, when compared with a group of mock-vaccinated animals, indicating the absence of residual virulence. Interestingly, an infectious virus could not be detected in the blood samples of the ASFV-G-∆I177L/∆EP402R-inoculated animals in either group at any of the time points tested. Furthermore, while all of the mock-inoculated animals presented a quick and lethal clinical form of ASF after the intramuscular inoculation challenge with 102 HAD50 of highly virulent parental field isolate Georgia 2010 (ASFV-G), all of the ASFV-G-∆I177L/∆EP402R-inoculated animals were protected, remaining clinically normal until the end of the observational period. Most of the ASFV-G-∆I177L/∆EP402R-inoculated pigs developed strong virus-specific antibody responses against viral antigens, reaching maximum levels at 28 days post inoculation. Importantly, all of the sera collected at that time point in the ASFV-G-∆I177L/∆EP402R-inoculated pigs did not react in a direct ELISA coated with the recombinant EP402R protein. Conversely, the EP402R protein was readily recognized by the pool of sera from the animals immunized with recombinant live attenuated vaccine candidates ASFV-G-∆I177L, ASFV-G-∆MGF, or ASFV-G-∆9GL/∆UK. Therefore, ASFV-G-∆I177L/∆EP402R is a novel, safe and efficacious candidate with potential to be used as an antigenically DIVA vaccine.

virology

What problem does this paper attempt to address?

The paper mainly addresses the following key issues: 1. **Development of a new vaccine**: Researchers developed a new candidate vaccine, ASFV-G-∆I177L/∆EP402R, by deleting the EP402R gene from a live attenuated vaccine strain of the African swine fever virus (ASFV), ASFV-G-∆I177L. 2. **Ensuring vaccine safety**: The new vaccine, when administered to domestic pigs, did not show any clinical symptoms or residual toxicity even at high doses (10^6 HAD50), demonstrating good safety. 3. **Enhancing vaccine efficacy**: This vaccine effectively protected domestic pigs from the highly pathogenic wild-type virus (ASFV-G). All animals vaccinated with this vaccine remained healthy and showed no signs of clinical disease when challenged 28 days post-vaccination. 4. **Achieving DIVA differentiation**: By deleting the EP402R gene, animals vaccinated with the new vaccine can be distinguished from those infected with the wild-type virus through serological testing, achieving Differentiating Infected from Vaccinated Animals (DIVA). Specifically, pigs vaccinated with ASFV-G-∆I177L/∆EP402R do not produce a specific antibody response to the EP402R protein, whereas pigs vaccinated with other ASFV strains do. In summary, this study developed a novel, safe, and effective ASFV candidate vaccine that not only provides effective immune protection against highly pathogenic ASFV but also allows for the differentiation of vaccinated animals from naturally infected animals through serological testing. This provides a powerful tool for the control of African swine fever.

Deletion of the EP402R Gene from the Genome of African Swine Fever Vaccine Strain ASFV-G-∆I177L Provides the Potential Capability of Differentiating between Infected and Vaccinated Animals

ASFV bearing an I226R gene-deletion elicits a robust immunity in pigs to African swine fever

Towards Safe African Swine Fever Vaccines: The A137R Gene as a Tool to Reduce Virulence and a Promising Serological DIVA Marker Candidate

Combinational Deletions of MGF360-9L and MGF505-7R Attenuated Highly Virulent African Swine Fever Virus and Conferred Protection against Homologous Challenge

Deletion of CD2-Like (CD2v) and C-Type Lectin-Like (EP153R) Genes from African Swine Fever Virus Georgia-∆9GL Abrogates Its Effectiveness as an Experimental Vaccine

The Development of a Multiplex Real-Time Quantitative PCR Assay for the Differential Detection of the Wild-Type Strain and the MGF505-2R, EP402R and I177L Gene-Deleted Strain of the African Swine Fever Virus

ASF Vaccine Candidate ASFV-G-∆I177L Does Not Exhibit Residual Virulence in Long-Term Clinical Studies

BA71ΔCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilities

Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-ΔI177L

Evaluation of the Deletion of African Swine Fever Virus E111R Gene from the Georgia Isolate in Virus Replication and Virulence in Domestic Pigs

Deletion of the L7L-L11L Genes Attenuates ASFV and Induces Protection against Homologous Challenge

Safety, efficacy, and DIVA feasibility on a novel live attenuated classical swine fever marker vaccine candidate

Differential Effect of the Deletion of African Swine Fever Virus Virulence-Associated Genes in the Induction of Attenuation of the Highly Virulent Georgia Strain

Protection Evaluation of a New Attenuated ASFV by Deletion of the L60L and CD2v Genes against Homologous Challenge

ASFV-G-∆I177L as an Effective Oral Nasal Vaccine against the Eurasia Strain of Africa Swine Fever

Generation and Genetic Stability of a PolX and 5′ MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development

Deletion of African Swine Fever Virus Histone-like Protein, A104R from the Georgia Isolate Drastically Reduces Virus Virulence in Domestic Pigs

A Pool of Eight Virally Vectored African Swine Fever Antigens Protect Pigs against Fatal Disease

Deletion of the H240R Gene in African Swine Fever Virus Partially Reduces Virus Virulence in Swine

Growth Kinetics and Protective Efficacy of Attenuated ASFV Strain Congo with Deletion of the EP402 Gene

Deletion of E184L, a Putative DIVA Target from the Pandemic Strain of African Swine Fever Virus, Produces a Reduction in Virulence and Protection against Virulent Challenge